Despite the mechanisms underlying the repression of HRNR, FLG2, CRCT1, and KPRP expression in BCs being unclear, upregulations of these genes by taxifolin, along with taxifolin’s action in reducing 4T-1 tumor growth, imply an appealing possibility to target recurrent BCs with 1q21.3 amplification by taxifolin. This evidence concerns the gene CRCT1 and neoplasm.